Literature DB >> 3530782

Dosage adjustment for ceftazidime in patients with impaired renal function.

R van Dalen, T B Vree, A M Baars, E Termond.   

Abstract

Ceftazidime has good antibacterial activity against many Gram-negative micro-organisms including Ps. aeruginosa. The aim of the present study was to calculate a dosage adjustment regimen for renal failure patients and to test it in a second group of patients. A study was made of the pharmacokinetics of ceftazidime 1 g given as a single bolus i.v. injection in 20 patients in an intensive care unit with varying degrees of renal function, including patients on regular haemodialysis. The serum half-life of elimination (t1/2 beta) varied from 1.6 to 45 h depending on renal function. During haemodialysis the mean t1/2 was 4.7 h. A good correlation between the renal clearance of creatinine and ceftazidime was observed. In most patients protein binding was lower than previously observed. From the pharmacokinetic data, a dosage adjustment regimen for patients with renal insufficiency was calculated, which studies in 7 further patients showed to be effective.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3530782     DOI: 10.1007/bf00542421

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  28 in total

1.  Comparative multiple-dose pharmacokinetics of cefotaxime, moxalactam, and ceftazidime.

Authors:  R Lüthy; J Blaser; A Bonetti; H Simmen; R Wise; W Siegenthaler
Journal:  Antimicrob Agents Chemother       Date:  1981-11       Impact factor: 5.191

2.  Pharmacokinetics of ceftazidime in normal and uremic subjects.

Authors:  A Leroy; F Leguy; F Borsa; G R Spencer; J P Fillastre; G Humbert
Journal:  Antimicrob Agents Chemother       Date:  1984-05       Impact factor: 5.191

3.  Effect of bed rest on distribution and elimination of drugs.

Authors:  G Levy
Journal:  J Pharm Sci       Date:  1967-07       Impact factor: 3.534

4.  Ceftazidime and renal function.

Authors:  K Alestig; B Trollfors; R Andersson; L Olaison; M Suurküla; S R Norrby
Journal:  J Antimicrob Chemother       Date:  1984-02       Impact factor: 5.790

5.  Pharmacokinetics of ceftazidime in patients with renal insufficiency.

Authors:  L S Welage; R W Schultz; J J Schentag
Journal:  Antimicrob Agents Chemother       Date:  1984-02       Impact factor: 5.191

Review 6.  Drug dosage in renal disease.

Authors:  L Dettli
Journal:  Clin Pharmacokinet       Date:  1976       Impact factor: 6.447

7.  Comparative pharmacokinetics of ceftazidime and moxalactam.

Authors:  T B Tjandramaga; A Van Hecken; A Mullie; R Verbesselt; P J De Schepper; L Verbist
Journal:  Antimicrob Agents Chemother       Date:  1982-08       Impact factor: 5.191

8.  Ceftazidime treatment in intensive care patients.

Authors:  R van Dalen; H L Muytjens; J S Gimbrère
Journal:  J Antimicrob Chemother       Date:  1983-07       Impact factor: 5.790

9.  The comparative pharmacokinetics of ceftazidime and cefotaxime in healthy volunteers.

Authors:  S M Harding; A J Monro; J E Thornton; J Ayrton; M I Hogg
Journal:  J Antimicrob Chemother       Date:  1981-09       Impact factor: 5.790

Review 10.  Clinical pharmacokinetics of the third generation cephalosporins.

Authors:  L Balant; P Dayer; R Auckenthaler
Journal:  Clin Pharmacokinet       Date:  1985 Mar-Apr       Impact factor: 6.447

View more
  14 in total

1.  Pharmacokinetic-pharmacodynamic evaluation of ceftazidime continuous infusion vs intermittent bolus injection in septicaemic melioidosis.

Authors:  B J Angus; M D Smith; Y Suputtamongkol; H Mattie; A L Walsh; V Wuthiekanun; W Chaowagul; N J White
Journal:  Br J Clin Pharmacol       Date:  2000-08       Impact factor: 4.335

2.  Suboptimal antimicrobial drug exposure in patients with renal impairment.

Authors:  David Czock; Martino Spitaletta; Frieder Keller
Journal:  Int J Clin Pharm       Date:  2015-05-28

3.  Pharmacodynamic target attainment for various ceftazidime dosing schemes in high-flux hemodialysis.

Authors:  Angela S Loo; Michael Neely; Evan J Anderson; Cybele Ghossein; Milena M McLaughlin; Marc H Scheetz
Journal:  Antimicrob Agents Chemother       Date:  2013-09-09       Impact factor: 5.191

Review 4.  Considerations in dosage selection for third generation cephalosporins.

Authors:  J H Yuk-Choi; C H Nightingale; T W Williams
Journal:  Clin Pharmacokinet       Date:  1992-02       Impact factor: 6.447

5.  Pharmacokinetic-pharmacodynamic evaluation of ceftazidime continuous infusion vs intermittent bolus injection in septicaemic melioidosis.

Authors:  B J Angus; M D Smith; Y Suputtamongkol; H Mattie; A L Walsh; V Wuthiekanun; W Chaowagul; N J White
Journal:  Br J Clin Pharmacol       Date:  2000-05       Impact factor: 4.335

Review 6.  Pharmacokinetics of drugs used in critically ill adults.

Authors:  B M Power; A M Forbes; P V van Heerden; K F Ilett
Journal:  Clin Pharmacokinet       Date:  1998-01       Impact factor: 6.447

7.  Pharmacokinetics of antibiotics in critically ill patients.

Authors:  R van Dalen; T B Vree
Journal:  Intensive Care Med       Date:  1990       Impact factor: 17.440

8.  Influence of protein binding and severity of illness on renal elimination of four cephalosporin drugs in intensive-care patients.

Authors:  R Van Dalen; T B Vree; I M Baars
Journal:  Pharm Weekbl Sci       Date:  1987-04-24

9.  Pharmacokinetics of cefradine, sulfamethoxazole and trimethoprim and their metabolites in a patient with peritonitis undergoing continuous ambulatory peritoneal dialysis.

Authors:  M Martea; Y A Hekster; T B Vree; A J Voets; J H Berden
Journal:  Pharm Weekbl Sci       Date:  1987-04-24

10.  Deterioration of kidney function by high doses of co-trimoxazole in man.

Authors:  T B Vree; M Martea; Y A Hekster; E F Termond; R Van Klaveren; J W Lammers; J H Berden
Journal:  Pharm Weekbl Sci       Date:  1987-04-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.